Ideaya Biosciences, Inc. (IDYA) — SEC Filings
Ideaya Biosciences, Inc. (IDYA) — 50 SEC filings. Latest: 8-K (May 5, 2026). Includes 26 8-K, 10 SC 13G/A, 5 10-Q.
View Ideaya Biosciences, Inc. on SEC EDGAR
Overview
Ideaya Biosciences, Inc. (IDYA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: IDEAYA Biosciences, Inc. announced on December 9, 2025, the termination of a material definitive agreement. The company, incorporated in Delaware, filed this 8-K report on December 12, 2025, detailing the event. The specific details of the agreement and the reasons for its termination are not elabor
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 7 bullish, 2 bearish, 41 neutral. The dominant filing sentiment for Ideaya Biosciences, Inc. is neutral.
Filing Type Overview
Ideaya Biosciences, Inc. (IDYA) has filed 26 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 10 SC 13G/A, 1 10-Q/A, 4 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of IDYA's 33 recent filings, 1 were flagged as high-risk, 20 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $207.834M |
| Net Income | $119.244M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $298.927M |
| Operating Margin | N/A |
| Total Assets | $1.185B |
| Total Debt | N/A |
Key Executives
- Dr. Paul R. Hastings
- Yujiro S. Nakagawa
- Dr. David M. Park
- Andres Ruiz Briseno
- Dr. S. Mark Smith
- Dr. S. Mark Albagli
- Ms. Sarah E. Kelly
- Abigail P. Johnson
Industry Context
The biotechnology sector, particularly in oncology, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like IDEAYA Biosciences compete by developing innovative therapies targeting specific genetic mutations or pathways. Success often hinges on securing strategic partnerships and demonstrating clinical efficacy to gain regulatory approval and market access.
Top Tags
biotech (5) · Biotechnology (4) · financing (4) · institutional-ownership (4) · material-agreement (3) · executive-compensation (3) · corporate-governance (3) · 10-Q (3) · amendment (3) · IDEAYA Biosciences (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Collaboration Revenue | $207.834M | Generated in Q3 2025, up from $0 in Q3 2024, driving profitability. |
| Net Income | $119.244M | Reported for Q3 2025, a significant swing from a $51.821M net loss in Q3 2024. |
| Net Loss (9 months) | $30.425M | Reduced from $144.165M in the prior year, indicating improving financial health. |
| Cash and Cash Equivalents | $298.927M | As of Sept 30, 2025, a substantial increase from $84.378M at Dec 31, 2024. |
| Research and Development Expenses | $82.993M | Increased in Q3 2025 from $57.152M in Q3 2024, reflecting ongoing pipeline investment. |
| Common Shares Outstanding | 87,666,408 | As of Oct 31, 2025, indicating potential dilution from prior offerings. |
| Net Proceeds from ATM Offering | $25.0M | Raised during the nine months ended Sept 30, 2025, contributing to liquidity. |
| Total Assets | $1.185B | As of Sept 30, 2025, demonstrating a strong balance sheet. |
| Gross Proceeds | $175.1M | From public offering |
| Shares Sold | 10.3M | In public offering |
| Price Per Share | $17.00 | For public offering |
| Net Loss | $49.7M | Increased from $40.1M in Q2 2024, indicating higher burn. |
| R&D Expenses | $43.9M | Increased from $38.9M in Q2 2024, driven by clinical trials. |
| Registrant's telephone number | 650-443-6209 | Contact information for IDEAYA Biosciences, Inc. |
| Reporting Period End Date | 20250331 | Indicates the end of the fiscal quarter for this filing. |
Forward-Looking Statements
- {"claim":"IDEAYA Biosciences' stock price will experience increased stability due to significant institutional backing.","entity":"IDEAYA Biosciences","targetDate":"next 6-12 months","confidence":"medium"}
- {"claim":"Other institutional investors may consider initiating or increasing positions in IDEAYA Biosciences, following FMR LLC's lead.","entity":"IDEAYA Biosciences","targetDate":"next 3-6 months","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Ideaya Biosciences, Inc. (IDYA)?
Ideaya Biosciences, Inc. has 50 recent SEC filings from Jan 2024 to May 2026, including 26 8-K, 10 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IDYA filings?
Across 50 filings, the sentiment breakdown is: 7 bullish, 2 bearish, 41 neutral. The dominant sentiment is neutral.
Where can I find Ideaya Biosciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Ideaya Biosciences, Inc. (IDYA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Ideaya Biosciences, Inc.?
Key financial highlights from Ideaya Biosciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IDYA?
The investment thesis for IDYA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Ideaya Biosciences, Inc.?
Key executives identified across Ideaya Biosciences, Inc.'s filings include Dr. Paul R. Hastings, Yujiro S. Nakagawa, Dr. David M. Park, Andres Ruiz Briseno, Dr. S. Mark Smith and 3 others.
What are the main risk factors for Ideaya Biosciences, Inc. stock?
Of IDYA's 33 assessed filings, 1 were flagged high-risk, 20 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Ideaya Biosciences, Inc.?
Recent forward-looking statements from Ideaya Biosciences, Inc. include guidance on {"claim":"IDEAYA Biosciences' stock price will experience increased stability due to significant institutional backing." and 1 other predictions.